| Autor: |
Zubarovskaya LS; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Moiseev IS; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Vladovskaya MD; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Mikhailova NB; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Morozova EV; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Bykova TA; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Vlasova YY; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Paina OV; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Kazantsev IV; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Slesarchuk OA; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Smirnova AG; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Osipova AA; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Stelmakh LV; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Polushin AY; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Goloshchapov OV; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Bogomolny MP; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Estrina MA; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Popova MO; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Kucher MA; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Volkova AG; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Alyansky AL; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Pevtcov DE; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Ivanova NE; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Babenko EV; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Mamaev NN; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Gindina TL; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Vitrishchak AA; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Chukhlovin AB; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Semenova EV; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Bondarenko SN; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Kulagin AD; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia., Afanasyev BV; RM Gorbacheva Research Institute, Pavlov University, 197022 Saint-Petersburg, Russia. |
| Abstrakt: |
In this single-center analysis, we evaluated the trends in 5185 hematopoietic cell transplantations performed between 1990 and 2022. The study group comprised 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) hematopoietic cell transplantations. In the multivariate analysis, there was an improvement in event-free-survival (EFS) after autoHCT (HR 0.6, 95% CI 0.4-0.7, p < 0.0001) due to reduced cumulative incidence of relapse in the last five years (56% in 2010-2014 vs. 38% in 2015-2022). An improvement in EFS after alloHCT over time was observed (HR 0.33, 95% CI 0.23-0.48, p < 0.0001), which was due to reduced non-relapse mortality. No difference in cumulative relapse incidence was observed over the last decade for allografted patients. Survival after autoHCT improved in Hodgkin's disease (HR 0.1, 95% CI 0.1-0.3), multiple myeloma (HR 0.4, 95% CI 0.2-0.7) and solid tumors (HR 0.2, 95% CI 0.2-0.4), while after alloHCT, improvement was observed in acute myeloid leukemia (HR 0.3, 95% CI 0.1-0.5), acute lymphoblastic leukemia (HR 0.2, 95% CI 0.1-0.5), Hodgkin's disease (HR 0.1, 95% CI 0.0-0.4), non-Hodgkin's lymphomas and chronic lymphocytic leukemia (HR 0.2, 95% CI 0.0-0.6), inborn diseases (HR 0.2, 95% CI 0.2-0.4) and acquired aplastic anemia with matched related donors and matched unrelated donors (HR 0.3, 95% CI 0.2-0.8). |
